167 related articles for article (PubMed ID: 37070563)
21. Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Harrison DJ; Qumseya A; Xue W; Arnold M; Lautz TB; Hiniker SM; Thomas SM; Venkatramani R; Weiss AR; Mascarenhas L
Pediatr Blood Cancer; 2024 Apr; 71(4):e30847. PubMed ID: 38282125
[TBL] [Abstract][Full Text] [Related]
22. Survival of patients with orbital and eyelid rhabdomyosarcoma treated on Children's Oncology Group studies from 1997 to 2013: A report from the Children's Oncology Group.
Metts J; Xue W; Gao Z; Ermoian R; Bradley JA; Arnold MA; Dasgupta R; Venkatramani R; Walterhouse D
Cancer; 2023 Jun; 129(11):1735-1743. PubMed ID: 36857314
[TBL] [Abstract][Full Text] [Related]
23. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Burke M; Anderson JR; Kao SC; Rodeberg D; Qualman SJ; Wolden SL; Meyer WH; Breitfeld PP;
J Clin Oncol; 2007 Nov; 25(31):4909-13. PubMed ID: 17971587
[TBL] [Abstract][Full Text] [Related]
24. Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Vasquez JC; Luo LY; Hiniker SM; Rhee DS; Dasgupta R; Chen S; Weigel BJ; Xue W; Venkatramani R; Arndt CA
Pediatr Blood Cancer; 2023 Jun; 70(6):e30293. PubMed ID: 36916768
[TBL] [Abstract][Full Text] [Related]
25. Optimal management strategies for rhabdomyosarcoma in children.
Walterhouse D; Watson A
Paediatr Drugs; 2007; 9(6):391-400. PubMed ID: 18052409
[TBL] [Abstract][Full Text] [Related]
26. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.
Smith LM; Anderson JR; Qualman SJ; Crist WM; Paidas CN; Teot LA; Pappo AS; Link MP; Grier HE; Wiener ES; Breneman JC; Raney RB; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Oct; 19(20):4058-64. PubMed ID: 11600608
[TBL] [Abstract][Full Text] [Related]
27. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
Spunt SL; Million L; Chi YY; Anderson J; Tian J; Hibbitts E; Coffin C; McCarville MB; Randall RL; Parham DM; Black JO; Kao SC; Hayes-Jordan A; Wolden S; Laurie F; Speights R; Kawashima E; Skapek SX; Meyer W; Pappo AS; Hawkins DS
Lancet Oncol; 2020 Jan; 21(1):145-161. PubMed ID: 31786124
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.
Breneman JC; Lyden E; Pappo AS; Link MP; Anderson JR; Parham DM; Qualman SJ; Wharam MD; Donaldson SS; Maurer HM; Meyer WH; Baker KS; Paidas CN; Crist WM
J Clin Oncol; 2003 Jan; 21(1):78-84. PubMed ID: 12506174
[TBL] [Abstract][Full Text] [Related]
29. Results of RS-99 protocol for childhood solid tumors.
Cai JY; Tang JY; Pan C; Xu M; Xue HL; Zhou M; Dong L; Ye QD; Jiang H; Shen SH; Chen J
World J Pediatr; 2010 Feb; 6(1):43-9. PubMed ID: 20143210
[TBL] [Abstract][Full Text] [Related]
30. Treatment Approach and Outcomes in Infants With Localized Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Bradley JA; Kayton ML; Chi YY; Hawkins DS; Tian J; Breneman J; Wolden SL; Walterhouse D; Rodeberg DA; Donaldson SS
Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):19-27. PubMed ID: 30138647
[TBL] [Abstract][Full Text] [Related]
31. Metabolic response as assessed by
Harrison DJ; Chi YY; Tian J; Hingorani P; Mascarenhas L; McCowage GB; Weigel BJ; Venkatramani R; Wolden SL; Yock TI; Rodeberg DA; Hayes-Jordan AA; Teot LA; Spunt SL; Meyer WH; Hawkins DS; Shulkin BL; Parisi MT
Cancer Med; 2021 Feb; 10(3):857-866. PubMed ID: 33340280
[TBL] [Abstract][Full Text] [Related]
32. Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997).
Neville HL; Andrassy RJ; Lobe TE; Bagwell CE; Anderson JR; Womer RB; Crist WM; Wiener ES
J Pediatr Surg; 2000 Feb; 35(2):317-21. PubMed ID: 10693687
[TBL] [Abstract][Full Text] [Related]
33. Soft tissue sarcomas arising in the retroperitoneal space in children. A report from the Intergroup Rhabdomyosarcoma Study (IRS) Committee.
Crist WM; Raney RB; Tefft M; Heyn R; Hays DM; Newton W; Beltangady M; Maurer HM
Cancer; 1985 Oct; 56(8):2125-32. PubMed ID: 3896467
[TBL] [Abstract][Full Text] [Related]
34. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
Crist WM; Anderson JR; Meza JL; Fryer C; Raney RB; Ruymann FB; Breneman J; Qualman SJ; Wiener E; Wharam M; Lobe T; Webber B; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Jun; 19(12):3091-102. PubMed ID: 11408506
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
[TBL] [Abstract][Full Text] [Related]
36. Local therapy is critical in localised pelvic rhabdomyosarcoma: experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee.
Réguerre Y; Martelli H; Rey A; Rogers T; Gaze M; Ben Arush MW; Devalck C; Oberlin O; Stevens M; Orbach D
Eur J Cancer; 2012 Sep; 48(13):2020-7. PubMed ID: 22154650
[TBL] [Abstract][Full Text] [Related]
37. Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV.
Pappo AS; Meza JL; Donaldson SS; Wharam MD; Wiener ES; Qualman SJ; Maurer HM; Crist WM
J Clin Oncol; 2003 Feb; 21(4):638-45. PubMed ID: 12586800
[TBL] [Abstract][Full Text] [Related]
38. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma.
Weigel BJ; Breitfeld PP; Hawkins D; Crist WM; Baker KS
J Pediatr Hematol Oncol; 2001; 23(5):272-6. PubMed ID: 11464981
[TBL] [Abstract][Full Text] [Related]
39. Perianal/perineal rhabdomyosarcoma: Results of the SIOP MMT 95, Italian RMS 96, and EpSSG RMS 2005 studies.
Rogers T; Zanetti I; Coppadoro B; Martelli H; Jenney M; Minard-Colin V; Terwisscha van Scheltinga SEJ; Skerritt C; Fajardo RD; Guérin F; Kelsey A; Merks JHM; Mandeville H; Guillén G; Glosli H; De Corti F; Bisogno G
Pediatr Blood Cancer; 2022 Sep; 69(9):e29739. PubMed ID: 35460336
[TBL] [Abstract][Full Text] [Related]
40. Durability of oncological outcomes of combination chemotherapy as a monotherapy for a select patient subset with non-metastatic non-alveolar bladder/prostate rhabdomyosarcoma.
Abdelhalim A; Atwa AM; Helmy TE; Dawaba ME; Elashry R; Hafez AT
J Pediatr Urol; 2021 Aug; 17(4):535.e1-535.e8. PubMed ID: 34092511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
